USP2 inhibitor ML364 dials down NLRP3 inflammasome activity in mouse gout and colitis models
A deubiquitinase called USP2 stabilizes NLRP3. Blocking it with ML364 cut inflammation in cells and in mouse peritonitis and colitis models.
Summary
The NLRP3 inflammasome is an immune sensor that, when overactive, drives inflammation linked to many age-related diseases. This study found that an enzyme called USP2 helps keep NLRP3 protein from being broken down by stripping off the ubiquitin tags that mark it for disposal. When USP2 was knocked down or blocked with the small molecule ML364, NLRP3 protein levels fell and inflammasome output dropped, including caspase-1 activation and IL-1β release. In mice, ML364 reduced neutrophil recruitment, IL-1β, and tissue injury in a gout-crystal peritonitis model and in a chemically induced colitis model. The work was done in mouse cells and mice only. Nothing here shows safety or benefit in people, and effects on lifespan or healthspan were not tested.
Detailed Summary
Chronic, low-grade inflammation is a recognized driver of aging and age-related disease, and the NLRP3 inflammasome is one of its central engines. NLRP3 senses danger signals and triggers release of the inflammatory cytokine IL-1β. Finding new ways to control how much NLRP3 protein a cell holds could open new routes to damping that process.
This study asked whether the deubiquitinase USP2 regulates NLRP3, and whether its inhibitor ML364 could suppress inflammasome-driven disease. Researchers used a murine macrophage line (J774A.1), HEK293 cells, and bone marrow-derived macrophages, applying genetic knockdown, overexpression, and drug inhibition. They measured protein interactions, ubiquitination, ASC speck formation, caspase-1 activation, and IL-1β secretion. In vivo, ML364 was tested in mouse models of monosodium urate (MSU)-induced peritonitis and dextran sulfate sodium (DSS)-induced colitis.
The mechanism: USP2 binds the NACHT domain of NLRP3 and removes ubiquitin chains, which stabilizes the protein. Without USP2, NLRP3 became more ubiquitinated and less abundant in macrophages. A catalytically inactive USP2 mutant could not support inflammasome activation, indicating the enzyme activity itself matters. Knockdown or ML364 treatment reduced caspase-1 activation, IL-1β release, and pyroptotic responses in cells. In mice, ML364 lowered neutrophil recruitment, IL-1β production, and tissue injury in both the peritonitis and colitis models.
These results move the mechanism and show functional improvement in acute inflammatory disease models. They do not address lifespan or healthspan, and no aging models were used. The finding adds USP2 to the list of regulators controlling NLRP3 stability and nominates ML364 as a tool compound worth watching.
Caveats are important. This is entirely preclinical, in mouse cells and mice, with acute models rather than chronic age-related inflammation. The abstract does not report group sizes, dosing, or off-target and toxicity data. USP2 has other cellular roles, so inhibiting it may have effects beyond NLRP3. Human relevance remains unproven.
Key Findings
- Mechanism: USP2 binds the NLRP3 NACHT domain and removes ubiquitin chains, stabilizing NLRP3 protein in mouse macrophages.
- USP2 knockdown or ML364 reduced caspase-1 activation, IL-1β release, and pyroptotic responses in cultured cells.
- A catalytically inactive USP2 mutant failed to support inflammasome activation, implicating its enzyme activity.
- Function in mice: ML364 reduced neutrophil recruitment, IL-1β, and tissue injury in MSU peritonitis and DSS colitis models.
- Lifespan, aging models, safety, and human data were not reported; this is mouse and cell evidence only.
Methodology
Preclinical study using J774A.1 murine macrophages, HEK293 cells, and primary bone marrow-derived macrophages, with knockdown, overexpression, a catalytically dead mutant, and ML364 inhibition. Readouts included immunoprecipitation, ubiquitination assays, ASC specks, caspase-1 and IL-1β. In vivo efficacy was tested in MSU peritonitis and DSS colitis mouse models.
Study Limitations
This summary is based on the abstract only, so sample sizes, dosing, statistics, and toxicity data were unavailable. The work is in mouse and cell models of acute inflammation, with no aging models, lifespan data, or human evidence, and off-target effects of USP2 inhibition were not described.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
